Blog

APCaRI members participate in the 2016 CCI Golf Classic

Members of the APCaRI team felt very fortunate yesterday to participate in the Alberta Cancer Foundation’s 28th Annual Cross Cancer Institute Golf Classic – a wonderful event that has raised more than $12 million to pioneer revolutionary projects in support of patients at Alberta’s own Cross Cancer Institute and beyond.

Over the past 27 years, the Cross Cancer Institute Golf Classic has funded leading edge research, treatment and patient care programs at the Cross Cancer Institute. In 2016, the Alberta Cancer Foundation embarked on a new investment that will bring together the brightest minds in colorectal cancer research to increase survival rates and improve quality of life for colorectal patients across the province.

Heartfelt thanks to the amazing volunteers, the organizing committee, the Alberta Cancer Foundation, and all of the participants!

 

 

 

New platform for prostate cancer diagnosis to be presented at ISEV 2017

The Lewis Research Group will present exciting results about new blood tests for prostate cancer during 3 talks at the upcoming 2017 International Society of Extracellular Vesicles (ISEV) annual meeting in Toronto (May 18-21). ISEV is a global society of researchers studying exosomes and microvesicles, which are the exciting new focus of cancer therapy and diagnosis.

Dr. Desmond Pink will speak about “Microflow cytometry: The Apogee A50 is a sensitive standard tool for extracellular vesicle analyses in liquid biopsies”, Robert Paproski’s presentation is entitled “Using machine learning of extracellular vesicle flow cytometry to build predictive fingerprints for prostate cancer diagnosis”, and Dr. John Lewis will speak about “An extracellular vesicle blood fingerprint distinguishes between patients with indolent and aggressive prostate cancer at diagnosis”.

The team is looking forward to sharing these key advances that were made possible through the APCaRI prospective cohort.

- John Lewis